101 related articles for article (PubMed ID: 24726313)
1. Detection of bladder cancer by measuring CD44v6 expression in urine with real-time quantitative reverse transcription polymerase chain reaction.
Hattori S; Kojima K; Minoshima K; Yamaha M; Horie M; Sawamura T; Kikuchi A; Deguchi T
Urology; 2014 Jun; 83(6):1443.e9-15. PubMed ID: 24726313
[TBL] [Abstract][Full Text] [Related]
2. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer.
Eissa S; Zohny SF; Swellam M; Mahmoud MH; El-Zayat TM; Salem AM
Clin Biochem; 2008 Nov; 41(16-17):1335-41. PubMed ID: 18804101
[TBL] [Abstract][Full Text] [Related]
3. The establishment of the duplex real-time RT-PCR assay for the detection of CD44v6 in pancreatic cancer patients and clinical application.
Zhou G; Chiu D; Qin D; Niu L; Cai J; He L; Huang W; Xu K
Biotechnol Appl Biochem; 2012; 59(1):55-63. PubMed ID: 22332746
[TBL] [Abstract][Full Text] [Related]
4. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR.
Guo B; Luo C; Xun C; Xie J; Wu X; Pu J
Exp Oncol; 2009 Mar; 31(1):43-7. PubMed ID: 19300416
[TBL] [Abstract][Full Text] [Related]
5. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
[TBL] [Abstract][Full Text] [Related]
6. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma.
Klein A; Zemer R; Buchumensky V; Klaper R; Nissenkorn I
Cancer; 1998 Jan; 82(2):349-54. PubMed ID: 9445193
[TBL] [Abstract][Full Text] [Related]
7. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.
Eissa S; Swellam M; Shehata H; El-Khouly IM; El-Zayat T; El-Ahmady O
J Urol; 2010 Feb; 183(2):493-8. PubMed ID: 20006858
[TBL] [Abstract][Full Text] [Related]
8. Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome.
Klatte T; Seligson DB; Rao JY; Yu H; de Martino M; Garraway I; Wong SG; Belldegrun AS; Pantuck AJ
J Urol; 2010 Jun; 183(6):2403-8. PubMed ID: 20403620
[TBL] [Abstract][Full Text] [Related]
9. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
[TBL] [Abstract][Full Text] [Related]
10. Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer.
Shimizu T; Suzuki H; Nojima M; Kitamura H; Yamamoto E; Maruyama R; Ashida M; Hatahira T; Kai M; Masumori N; Tokino T; Imai K; Tsukamoto T; Toyota M
Eur Urol; 2013 Jun; 63(6):1091-100. PubMed ID: 23200812
[TBL] [Abstract][Full Text] [Related]
11. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
[TBL] [Abstract][Full Text] [Related]
12. Comparison of seven screening methods in the diagnosis of bladder cancer.
Sun Y; He DL; Ma Q; Wan XY; Zhu GD; Li L; Luo Y; He H; Yang L
Chin Med J (Engl); 2006 Nov; 119(21):1763-71. PubMed ID: 17097029
[TBL] [Abstract][Full Text] [Related]
13. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
14. Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek® and urine cytology in the detection of transitional cell carcinoma of the bladder.
Al-Maghrebi M; Kehinde EO; Kapila K; Anim JT
Med Princ Pract; 2012; 21(3):295-7. PubMed ID: 22236881
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
16. Detection and clinical significance of CD44v6 and integrin-β1 in pancreatic cancer patients using a triplex real-time RT-PCR assay.
Zhou G; Chiu D; Qin D; Niu L; Cai J; He L; Huang W; Xu K
Appl Biochem Biotechnol; 2012 Aug; 167(8):2257-68. PubMed ID: 22695923
[TBL] [Abstract][Full Text] [Related]
17. Limitations of CD44v6 amplification for the detection of tumour cells in the blood of colorectal cancer patients.
Masson D; Denis MG; Lustenberger P
Br J Cancer; 2000 Apr; 82(7):1283-9. PubMed ID: 10755402
[TBL] [Abstract][Full Text] [Related]
18. Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data.
Casadio V; Calistri D; Tebaldi M; Bravaccini S; Gunelli R; Martorana G; Bertaccini A; Serra L; Scarpi E; Amadori D; Silvestrini R; Zoli W
Urol Oncol; 2013 Nov; 31(8):1744-50. PubMed ID: 23141783
[TBL] [Abstract][Full Text] [Related]
19. Rapid detection of urinary long non-coding RNA urothelial carcinoma associated one using a PCR-free nanoparticle-based assay.
Eissa S; Matboli M; Essawy NO; Shehta M; Kotb YM
Biomarkers; 2015; 20(3):212-7. PubMed ID: 26161701
[TBL] [Abstract][Full Text] [Related]
20. Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer.
Marín-Aguilera M; Mengual L; Ribal MJ; Ars E; Ríos J; Gázquez C; Villavicencio H; Alcaraz A
Urology; 2012 Jan; 79(1):240.e9-15. PubMed ID: 22055693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
